The global Recombinant Human Serum Albumin (HSA) Market is projected to reach USD 116.42 million by 2027, growing at a CAGR of 8.2% from USD 62.11 million in 2019. The market growth is driven by the extensive usage of recombinant DNA technology for drug delivery, drug formulation, cell culture media, vaccine production, and plasma research in laboratory settings.

Albumin is a group of acidic proteins found in human bodily fluids and tissues of plants and mammals, with the key function of regulating the colloidal osmotic pressure in the blood. Albumin is bifurcated into three types: bovine serum albumin, recombinant albumin, and human serum albumin.

Get a free sample PDF of the report, visit @

Recombinant human serum albumin is witnessing high demand due to its significant usage in replacing lost fluid and restoring blood volume during serious burn injuries, fetal erythroblastosis, hypoproteinemia, surgeries, and others. The product displays an excellent capacity to carry various ligands due to its hydrophobic properties, leading to increased demand for drug delivery applications.

Moreover, it is used in therapeutic medicine to treat low albumin levels caused by dialysis, surgery, abdominal infections, pancreatitis, liver failure, respiratory distress, ovarian disorders caused by fertility drugs, bypass surgery, and other health conditions. The extensive medical application of the product is poised to boost the recombinant human serum albumin market share.

The rise in FDA approvals for research, along with the development of contract research manufacturing of drugs, will also drive recombinant human serum albumin market trends through 2027. However, the use of albumin sourced from human plasma may lead to infection and disease transmission, which may hamper industry growth.

OsrHSA is anticipated to witness a major growth rate as it has higher purity and excellent batch consistency compared to other types of albumin. In terms of application, the cell culture media segment is estimated to exhibit a maximum CAGR through 2027, with plasma-derived human serum albumin extensively used for manufacturing cell culture-based vaccines and therapeutics.

To know more about the latest insights of the report, visit @

North America was the leading revenue contributor to the global recombinant human serum albumin market in 2019 and is expected to showcase significant growth through 2027 due to a rise in the approval of albumin products along with favorable medical research scenarios in the region. However, the Asia-Pacific region is forecast to register maximum CAGR over the analysis period due to a surge in healthcare expenditure along with growing awareness regarding the treatment with DNA recombinant technology.

The key players operating in the recombinant human serum albumin market are Albumedix, Merck, Ventria (InVitria), NCPC, Oryzogen, HiMedia, Boehringer Ingelheim, Regeneron Pharmaceuticals, Eli Liily, Bristol-Myers Squibb, Novartis, Celldex Therapeutics, Takeda, GlaxoSmithKline, Roche, and Cyagen Biosciences. These industry players are adopting several strategies such as acquisitions, mergers, collaborations, new product development, and capacity expansion, thereby supporting the overall growth of the market. Moreover, rising investments by the key industry players for R&D activities will further bolster industry growth. For instance, Merck announced the approved ERVEBO® (Ebola Zaire Vaccine sourced from recombinant human serum albumin) by the FDA on 20 December 2029, which can prevent disease caused by Zaire ebolavirus in individuals aged 18 years and older.

Request a customized copy of the report @

Thank you for reading our report. To inquire about customization or any query about the report, please get in touch with us. Our team will make sure the report is best suited to your needs.  

About Reports and Data 

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behaviour shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.


John W, Head of Business Development
Reports And Data | Web:
Direct Line: +1-212-710-1370
E-mail: [email protected]
LinkedIn | Twitter | Blogs